Human cytomegalovirus (CMV) is a widespread ␤-herpes virus that infects more than half of the Western population. Primary infection induces a life-long latent infection in the immunocompetent host with asymptomatic episodes of viral replication, which are controlled by a vigorous immune response. CMV infection is responsible for increased morbidity and mortality after allogeneic stem cell transplantation (SCT) as either CMV reactivation in CMV-seropositive patients or primary infection in CMV-seronegative patients receiving grafts from seropositive donors. Several studies have demonstrated a significant decline in a overall survival in human leukocyte antigen-identical sibling transplantations or in unrelated transplantations where either the donor or the patient was CMV-seropositive. 1, 2 The central mechanism controlling CMV infection is mediated by antigen-specific CD8 ϩ cytotoxic and CD4 ϩ ␣␤ T lymphocytes and natural killer (NK) cells. [3] [4] [5] CMV-specific CD3 ϩ CD8 ϩ CD28 Ϫ CD57 ϩ ␣␤ T cells are regarded as the principle effector cells controlling CMV reactivation. 6,7 Both humoral and cellular immunity is involved in protective immune responses to CMV reactivation and CMV resolution. 8 Recent interest has focused on ␥␦ T cells and their role in immune responses during CMV infection. ␥␦ T cells are often termed the "unconventional" T cells and represent a minor population of circulating T cells (Ͻ 5%) in humans but are present in large numbers in epithelial tissues. [9] [10] [11] [12] [13] In contrast to ␣␤ T cells, which recognize peptides bound to major histocompatibility complex (MHC) class I or class II molecules, most ␥␦ T cells lack surface expression of CD4 or CD8 and display a non-MHC-restricted recognition. 14, 15 There are 2 major subsets of ␥␦ T cells present in human peripheral blood: a subset of ␥␦ T cells expressing a T-cell receptor (TCR) encoded by the V␦2 and V␥9 gene segments, which accounts for 50% to 90% of ␥␦ T cells in adult peripheral blood and a minor V␦1 subset more frequent at mucosal epithelium sites, such as skin and the intestine. An additional small subset of V␦3 ␥␦ T cells is also present in peripheral blood but represents a minor population of less than 0.1% of CD3 ϩ T cells. The ␥␦ T cells recognize ligands that are not seen by ␣␤ T cells and provide additional means by which the immune system can maintain local immunosurveillance with immediate tumor defense, selective recognition of viral antigens, and bacterial metabolites. 12, 14 V␦1 ␥␦ T cells recognize ligands for an activating receptor NKG2D, such as MHC class I-related chain A (MICA and MICB) stress-induced antigens expressed on epithelial tumor cells, some leukemias, lymphomas, and the UL16-binding proteins. [16] [17] [18] [19] [20] [21] [22] [23] [24] V␦2 ␥␦ T cells recognize low molecular weight nonpeptidic phosphoantigens, particularly intermediates of the nonmevalonate pathway of bacterial isoprenoid biosynthesis 25 or isopenthenyl pyrophosphate and aminobiphosphonates in eukaryotic cells. 26 Recent studies have shown expansion and cytotoxic function of CMV-reactive V␦1 and V␦3 ␥␦ T cells in the peripheral blood of patients receiving renal and lung allografts. [27] [28] [29] [30] [31] In the present study, we analyzed the relative numbers of the V␦2neg (V␦1 and V␦3 ␥␦ T cells) compared with V␦2pos ␥␦ T cells in CMV-seropositive healthy healthy donors and in CMVseropositive patients with documented CMV reactivation after allogeneic SCT. We found major differences in frequencies, repertoire profiles, and cytotoxic effector function in response to Submitted January 15, 2010; accepted May 14, 2010. Prepublished online as Blood First Edition paper, June 24, 2010; DOI 10.1182/blood-2010-01-255166. *P.J.T. and M.W.L. contributed equally to this study and should be considered as joint senior authors.
Introduction
Human cytomegalovirus (CMV) is a widespread ␤-herpes virus that infects more than half of the Western population. Primary infection induces a life-long latent infection in the immunocompetent host with asymptomatic episodes of viral replication, which are controlled by a vigorous immune response. CMV infection is responsible for increased morbidity and mortality after allogeneic stem cell transplantation (SCT) as either CMV reactivation in CMV-seropositive patients or primary infection in CMV-seronegative patients receiving grafts from seropositive donors. Several studies have demonstrated a significant decline in a overall survival in human leukocyte antigen-identical sibling transplantations or in unrelated transplantations where either the donor or the patient was CMV-seropositive. 1, 2 The central mechanism controlling CMV infection is mediated by antigen-specific CD8 ϩ cytotoxic and CD4 ϩ ␣␤ T lymphocytes and natural killer (NK) cells. [3] [4] [5] CMV-specific CD3 ϩ CD8 ϩ CD28 Ϫ CD57 ϩ ␣␤ T cells are regarded as the principle effector cells controlling CMV reactivation. 6, 7 Both humoral and cellular immunity is involved in protective immune responses to CMV reactivation and CMV resolution. 8 Recent interest has focused on ␥␦ T cells and their role in immune responses during CMV infection. ␥␦ T cells are often termed the "unconventional" T cells and represent a minor population of circulating T cells (Ͻ 5%) in humans but are present in large numbers in epithelial tissues. [9] [10] [11] [12] [13] In contrast to ␣␤ T cells, which recognize peptides bound to major histocompatibility complex (MHC) class I or class II molecules, most ␥␦ T cells lack surface expression of CD4 or CD8 and display a non-MHC-restricted recognition. 14, 15 There are 2 major subsets of ␥␦ T cells present in human peripheral blood: a subset of ␥␦ T cells expressing a T-cell receptor (TCR) encoded by the V␦2 and V␥9 gene segments, which accounts for 50% to 90% of ␥␦ T cells in adult peripheral blood and a minor V␦1 subset more frequent at mucosal epithelium sites, such as skin and the intestine. An additional small subset of V␦3 ␥␦ T cells is also present in peripheral blood but represents a minor population of less than 0.1% of CD3 ϩ T cells. The ␥␦ T cells recognize ligands that are not seen by ␣␤ T cells and provide additional means by which the immune system can maintain local immunosurveillance with immediate tumor defense, selective recognition of viral antigens, and bacterial metabolites. 12, 14 V␦1 ␥␦ T cells recognize ligands for an activating receptor NKG2D, such as MHC class I-related chain A (MICA and MICB) stress-induced antigens expressed on epithelial tumor cells, some leukemias, lymphomas, and the UL16-binding proteins. [16] [17] [18] [19] [20] [21] [22] [23] [24] V␦2 ␥␦ T cells recognize low molecular weight nonpeptidic phosphoantigens, particularly intermediates of the nonmevalonate pathway of bacterial isoprenoid biosynthesis 25 or isopenthenyl pyrophosphate and aminobiphosphonates in eukaryotic cells. 26 Recent studies have shown expansion and cytotoxic function of CMV-reactive V␦1 and V␦3 ␥␦ T cells in the peripheral blood of patients receiving renal and lung allografts. [27] [28] [29] [30] [31] In the present study, we analyzed the relative numbers of the V␦2neg (V␦1 and V␦3 ␥␦ T cells) compared with V␦2pos ␥␦ T cells in CMV-seropositive healthy healthy donors and in CMVseropositive patients with documented CMV reactivation after allogeneic SCT. We found major differences in frequencies, repertoire profiles, and cytotoxic effector function in response to CMV between the ␥␦ T-cell subsets. Together, the results suggest a protective role of V␦2neg ␥␦ T cells during CMV reactivation in immunocompromised patients after SCT analogous to that seen in the previous studies of solid organ allografts.
Methods

Patients
A cohort of 40 patients undergoing allogeneic SCT at the Royal Free Hospital NHS Trust, London, United Kingdom was enrolled for this study after informed consent in accordance with the Declaration of Helsinki. All experiments involving patient samples were approved by the United Kingdom Home Office. Patient characteristics are listed in Table 1 . Patients were divided by CMV serostatus of their donors into 3 groups; CMVpositive patients with CMV-positive donors (CMV ϩ/ϩ , n ϭ 14), CMVnegative patients with CMV-negative donors (CMV Ϫ/Ϫ , n ϭ 20) and CMV mismatched; patient-donor pair CMV ϩ/Ϫ (n ϭ 2) and CMV Ϫ/ϩ (n ϭ 4). CMV serology of patients' and healthy donors was determined by the Architect i2000SR analyser (Abbott Diagnostic). Posttransplantation monitoring of CMV reactivation was performed by in-house TaqMan human CMV PCR as described previously. 32 Peripheral blood samples were collected from patients every 3 months during the 24-month follow-up after transplantation.
Healthy subjects
Peripheral blood samples from 45 age-matched healthy adult volunteers (31 females, 14 males) with median age 34 years (range, 21-53 years) were collected after obtaining informed consent. The cohort included CMV-seronegative (n ϭ 22) and CMV-seropositive (n ϭ 23) subjects. Peripheral blood mononuclear cells (PBMCs) were separated from heparinized whole blood using density gradient separation (Lymphoprep, Nycomed).
Antibodies
The following monoclonal antibodies (mAbs) were purchased from BD Biosciences: anti-TCR-␥␦-1, anti-CD3, anti-CD11a, anti-CD27, anti-CD45RO, and anti-CD45RA. Antibody directed against anti-V␦2 TCR was purchased from BD Biosciences PharMingen. Unlabeled antibodies anti-V␦1 TCR were from Beckman Coulter, anti-CD3 (OKT3), anti-IgG2a (eBioscience), anti-TCR-␥␦ and anti-IgG1 (BD Biosciences), and anti-NKG2D (R&D Systems).
Flow cytometric analysis
Freshly isolated PBMCs (2.5 ϫ 10 5 ) were labeled with specific mAbs at 4°C in the dark for 30 minutes and then washed twice in 2 mL of cold phosphate-buffered saline containing 2.5% of fetal calf serum (FCS, Invitrogen) and subsequently fixed in 100 L of 1% (wt/vol) paraformaldehyde (Sigma-Aldrich). Samples were acquired within 4 hours on a FACSCalibur (BD Biosciences) flow cytometer using CellQuest Version 3.3 software (BD Biosciences) and analyzed with FlowJo Version 8.6 software (TreeStar). The total lymphocyte population was gated based on forward versus side scatter followed by gating on CD3 ϩ and either V␦2pos ␥␦ T cell (the predominant population representing up to 3% circulating T cells; range, 0.32-14.10; median, 2.43) or the remaining V␦2neg ␥␦ T cells; consisting of V␦1 and V␦3 subsets (range, 0.02-7.56; median, 0.90). Because of a limited availability of specific V␦1 and V␦3 mAbs and very low frequencies present in the peripheral blood, the V␦1 and V␦3 subsets were combined as V␦2neg ␥␦ T cells. The absolute numbers of V␦2pos or V␦2neg ␥␦ T cells were determined by multiplying their percentages within the CD3 ϩ population by the absolute CD3 counts generated with staining of whole blood samples with TriTest (BD Biosciences) reagents in TruCount tubes. After red cell lysis, the samples were acquired within 30 minutes on a FACSCalibur and the absolute counts (cells/L) were calculated using the MultiSET software (BD Biosciences).
TCRV␦ 1, 2, 3-chains and TCRV␥8-chain CDR3 size spectratyping analysis
Total RNA was extracted from separated CD4 Ϫ CD8 Ϫ cell pellets using RNeasy kit (QIAGEN) and transcribed into complementary DNA (cDNA) according to the manufacturer's instructions (Promega). Each cDNA was amplified using primers for TCR V␦-1, 2, 3-chain variable and constant segments published previously 27 and primers for TCR V␥8-chain. 33 Aliquots of 2 L of the PCR products were then amplified with the same forward primer for each V␦-chain with C␦-FAM and V␥8-chain with C␥-FAM-labeled constant primer for 10 cycles with the same PCR conditions. Separations of the 2-L labeled products were performed using ABI 3130 DNA Sequencer (Applied Biosystems). Fluorescence intensity for each sample was analyzed with the GeneScan Version 3.0 software (Applied Biosystems).
Generation of polyclonal ␥␦ T-cell lines
Fresh PBMCs were isolated from peripheral blood of healthy volunteers and ␥␦ T cells were sorted from PBMCs using anti-V␦1 (Beckman Coulter) or anti-V␦2 (BD Biosciences PharMingen) mAbs and magnetic beads (Miltenyi Biotec). Sorted cells were expanded with modified protocol described previously. 28 Polyclonal ␥␦ T-cell cultures were established with 1 g/mL PHA-L (Sigma-Aldrich), 200 IU/mL of human recombinant IL-2 (R&D Systems), and irradiated allogeneic PBMCs (35 Gy). After 3 to 4 weeks of culture, polyclonal lines were immunophenotyped and purity (routinely Ͼ 95%) determined by multicolor fluorescent staining.
Infection of MRC5 fibroblasts
Human fetal lung fibroblasts MRC5 were obtained from European Collection of Cell Cultures. Cells were cultured in MEM supplemented with 2mM 
Diagnosis, no. (%)
Chronic myeloid leukemia, chronic phase 3 (7.5)
Acute myeloid leukemia 10 ( 
D indicates donor; and P, patient.
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BLOOD, 23 SEPTEMBER 2010 ⅐ VOLUME 116, NUMBER 12 For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From L-glutamine, nonessential amino acids (all from Sigma-Aldrich), and 10% FCS. Fibroblasts were used between 32 and 40 passages and were maintained at 37°C in a humid atmosphere containing 5% CO 2 .
Both clinical CMV strains TB40/E and VHL/E were kindly provided by Dr Sinzger (University of Tubingen, Tubingen, Germany); HSV-1 strain was provided by Dr Milne (UCL, London). For infection, 5 ϫ 10 5 MRC5 fibroblasts per well were seeded into 24-well plate 24 hours before adding the virus. Subconfluent monolayers of MRC5 fibroblasts were incubated with CMV (or HSV-1) suspension at multiplicity of infection of 1 to 5 for 2 hours at 37°C. After virus adsorption, cells were washed and cultured for 2 to 4 days. Infection was verified by microscopy to determine the cytopathic effect. Before the cocultures, cells were washed with PBS and used in cytotoxicity assays.
Cytotoxicity assays
Effector ␥␦ polyclonal cell lines were recovered from culture or cryopreservation and washed in Hanks buffered saline solution (Invitrogen) to remove FCS and culture media. Cells were resuspended in PKH26 diluent (Sigma-Aldrich) and labeled with PKH26 red fluorescent dye (Sigma-Aldrich) as described previously. 34 Labeled effector cells were coincubated at indicated effector/target ratios (E:Ts, 10:1 and 20:1) with CMV-infected fibroblasts or with noninfected fibroblasts as controls. Cytotoxicity was measured in duplicates after 4-hour coculture at 37°C. To-Pro-3 iodide (1M in PBS; Invitrogen) was added immediately before the acquisition on the flow cytometer. At least 10 000 target cells were acquired with 1024 channel resolution after gating out the red fluorescence of PKH26 dye and the proportion of To-Pro-3 iodide-positive cells. Background target cell death was determined from the cells incubated in the absence of effector cells. For the blocking assay, the effector cells were preincubated for 1 hour with 10 g/mL of anti-TCR-␥␦ or anti-TCR-V␦1, 10 g/mL of anti-CD3, 20 g/mL of anti-NKG2D, or control mouse IgG. Effector ␥␦ cells were coincubated for 4 hours at 10:1 E/T ratio with CMV-infected and uninfected fibroblasts.
IFN-␥ detection
The ␥␦ polyclonal cell lines were cocultured at 10:1 E/T ratio with CMV-infected and uninfected fibroblasts; and after 6 hours, cell-free supernatants were collected. Interferon-␥ (IFN-␥) release was determined by BD Cytometric Bead Array (CBA) from BD Biosciences according to the manufacturer's instructions. Samples were acquired on a FACSAria, and data were analyzed using the FCAP Version 1.0 software (BD Biosciences).
Statistical analyses
The statistical differences between CMV ϩ and CMV Ϫ groups were determined using the unpaired nonparametric Mann-Whitney U test using GraphPad Prism Version 4.0 software. Statistical significance was achieved when P was less than .05.
Results
V␦2neg ␥␦ T cells are significantly expanded in CMV-seropositive but not CMV-seronegative transplant recipients
Posttransplantation immune reconstitution of V␦2positive (V␦2pos) and V␦2negative (V␦2neg) ␥␦ T-cell subsets is shown in Figure 1A . The V␦2neg ␥␦ T cells showed a rapid reconstitution, reaching a plateau at the median of the normal range approximately 9 months after SCT. In contrast, the V␦2pos subset showed a delayed reconstitution with patients failing to reach the median of the normal range during the 2-year follow-up. Next, we determined the immune reconstitution of naive ␥␦ T-cell subsets in patients after SCT ( Figure 1B ), generally distinguished with CD27 ϩ CD45RA ϩ or CD45RO Ϫ phenotype 5 or as CD27 bright CD11a dull . 35 The absolute numbers of naive V␦2neg ␥␦ T cells reconstituted to normal levels within 6 months and were present at approximately the median counts from 9 months after transplantation. In contrast, the absolute numbers of naive V␦2pos cells recovered slowly, reached only the lower normal range at 6 months and remained below the median values at 2 years after SCT.
As patient-donor CMV status has been shown to have a profound impact on the immune reconstitution after SCT, we analyzed its effect on the reconstitution of ␥␦ T-cell subsets. The absolute numbers of CD3 ϩ V␦2pos versus V␦2neg ␥␦ T cells were compared between CMV-seropositive and CMV-seronegative allogeneic transplantation recipients (Figure 2) . During the first 6 months after transplantation, significantly higher absolute numbers of V␦2neg ␥␦ T cells were detected in CMV ϩ/ϩ patient-donor pairs compared with the CMV Ϫ/Ϫ pairs (P ϭ .02 and P ϭ .04, respectively) or to the CMV mismatched group; CMV ϩ/Ϫ (n ϭ 2) and CMV Ϫ/ϩ (n ϭ 4), (data not shown). These numbers were still elevated at 9 and 12 months after SCT. No significant differences were detected in the reconstitution of the V␦2pos subset between CMV ϩ/ϩ and CMV Ϫ/Ϫ patients. These results suggest that the expansion of V␦2neg ␥␦ T cells in lymphopenic patients is because of an initial or ongoing immune response to CMV infection in the early posttransplantation period when the immune reconstitution is incomplete.
We then analyzed the effect of CMV reactivation on the reconstitution of the V␦2neg ␥␦ T cells during the first 12 months after SCT. Patients with an early CMV reactivation after transplantation (n ϭ 6) showed large and long-lasting expansion of V␦2neg ␥␦ T cells compared with patients (n ϭ 8) with no CMV reactivation after transplantation ( Figure 3A) . However, this difference was not statistically significant, and larger patient groups would need to be analyzed.
Analysis of the subgroup of CMV Ϫ /Epstein-Barr virus (EBV) ϩ patients (n ϭ 14) showed no expansion of V␦2neg ␥␦ T cells during the posttransplantation follow-up ( Figure 3B ), suggesting that the V␦2neg cell expansion is not simply a nonspecific response to chronic latent viral infections or to posttransplantation lymphopenia.
Frequencies of V␦2neg ␥␦ T cells and of CD8 ϩ CD28 Ϫ CD57 ϩ ␣␤ T cells were monitored during the first 12 months after transplantation. No correlation between the aforementioned cell populations was found (P ϭ .453) in patients with CMV reactivation early after transplantation ( Figure 3C ). These results suggest that the expansions of V␦2neg ␥␦ T cells respond to active CMV infection that occurs in the absence of the CMV-specific ␣␤ T-cell response. In contrast, there was a significant correlation between CMV-reactive ␣␤ T cells and V␦2neg ␥␦ T cells (P Ͼ .002) in patients without CMV reactivation ( Figure 3D ). This may reflect the protective effect of CD8 ϩ CD28 Ϫ CD57 ϩ ␣␤ T cells and ongoing linkage between the innate and acquired immune response to CMV even in the presence of protective immunity.
V␦2negative ␥␦ T cells are increased in CMV-seropositive healthy subjects compared with CMV-seronegative persons
The absolute numbers of ␥␦ T-cell subsets were measured and compared between CMV-seropositive (n ϭ 23) and CMV-seronegative (n ϭ 22) healthy persons ( Figure 4A ). Significantly increased absolute numbers of V␦2neg cells were detected in CMV ϩ healthy persons compared with CMV Ϫ subject numbers (P Ͼ .001).
In contrast, absolute numbers of V␦2pos cells were comparable between the 2 groups (P Ͻ .883). These results demonstrate the impact of CMV status on ␥␦ T-cell subsets in anti-CMV immune responses in healthy immunocompetent donors. Although there was an apparent correlation between the frequencies and the absolute numbers of CMV-specific CD3 ϩ CD8 ϩ CD28 Ϫ CD57 ϩ ␣␤ T cells and V␦2neg ␥␦ T cells in healthy CMV ϩ persons, it failed to reach statistical significance (P ϭ .10 and P ϭ .16, respectively; Figure 4B ). Thus, the relationship between the anti-CMV ␣␤ The effect of the patient-donor CMV status on absolute counts of V␦2neg (top row) and V␦2pos ␥␦ T-cell subsets (bottom row) was analyzed in patients during 3, 6, 9, and 12 months after transplantation. Patients were divided into 2 groups: 14 CMV ϩ/ϩ and 20 CMV Ϫ/Ϫ . The horizontal bars represent the median values for each time point. The dashed line represents the median normal range generated from CMV ϩ healthy donors; and the dotted line, the median normal range generated from CMV Ϫ healthy donors. Available patient samples were analyzed using nonparametric Mann-Whitney test, and P values were determined. P values less than .05 were considered significant. BLOOD, 23 SEPTEMBER 2010 ⅐ VOLUME 116, NUMBER 12 For personal use only. on April 12, 2017. by guest www.bloodjournal.org From T cells and V␦2neg ␥␦ T cells seen early after transplantation is not so apparent in healthy CMV ϩ persons in whom the ␣␤ T-cell response is better established and probably dominant.
To determine whether the expansion of V␦2neg ␥␦ T cells in CMV ϩ healthy donors and patients is clonally restricted, we performed complementary-determining region (CDR3) spectratyping analysis of the TCR-␦ chain repertoire. We scored the complexity of TCR-␦ chains repertoire by counting the total number of peaks in each histogram. Healthy donors show Gaussian profiles of approximately 18 or more peaks representing different CDR3 length rearrangements, with dominant peaks above the normal distribution that identify expansions of one or several clones. Representative profiles of monoclonal (1 peak), oligoclonal (2-5 peaks), and polyclonal (8 and more peaks) distributions are shown in Figure 5 . CDR3 profiles of the V␦1, V␦2, and V␦3 subsets were generated in 13 CMV ϩ and 12 CMV Ϫ randomly selected healthy adults and in 8 CMV ϩ/ϩ patients at multiple time points after transplantation, as shown in Figure 6 .
In the majority of healthy CMV ϩ donors, the V␦1 cells showed oligoclonal profiles in addition to 2 monoclonal expansions; in comparison, CMV Ϫ donors showed equal numbers of oligoclonal and polyclonal V␦1 repertoires. Interestingly, the V␦3 profiles were predominantly oligoclonal regardless of CMV serostatus, and the decreased diversity was evident with only one of 13 CMV ϩ and 1/12 CMV Ϫ healthy donor showing polyclonal distributions. Overall, the majority of V␦2pos ␥␦ T cells displayed polyclonal TCR repertoires both in CMV ϩ and CMV Ϫ persons. Together, these results indicate that the peripheral expansions of the V␦2neg ␥␦ T cells in CMV infection in healthy donors are restricted to some degree but do not strictly correlate with CDR3-dependent selection.
The reconstituted TCR repertoire of V␦1 and V␦2 T cells in CMV ϩ/ϩ patients showed significantly restricted CDR3 profiles at 3 months after transplantation (P ϭ .04 and P ϭ .01, respectively) regardless of whether or not the patients had CMV reactivation. Both subsets gradually increased their diversity at 6 months, resulting in polyclonal distribution at 12 months. TCR profiles of the V␦3 subset remained mostly oligoclonal during the follow-up and showed significantly more polyclonal repertoire than healthy donors at 12 months. The reconstitution of the TCR repertoire of the V␦1, V␦2, and V␦3 subsets in CMV Ϫ patients with CMV Ϫ donors showed a relatively wider range of oligoclonal and polyclonal profiles. Taken together, we could find no evidence of a CMV-driven clonal expansion of V␦2neg ␥␦ T cells in healthy persons or in transplantation recipients.
Recently, a public V␥8V␦1 TCR has been identified in CMV-infected newborns 33 ; therefore, we analyzed V␥8 profiles in 35 randomly selected healthy adults (CMV ϩ , n ϭ 19, CMV Ϫ , n ϭ 16), as shown in Figure 6D . Oligoclonal V␥8 repertoires were found in both groups regardless of CMV serostatus in the . CMV seropositivity in healthy persons is associated with significantly higher absolute counts of V␦2neg ␥␦ T cells. (A) Healthy donors were divided by their CMV status into CMV ϩ (n ϭ 23) and CMV Ϫ (n ϭ 22) groups. Samples were gated on live lymphocytes as side scatter versus forward scatter followed by gating on CD3 ϩ and V␦2pos or V␦2neg (left) ␥␦ T-cell subset. Absolute counts of both cell subsets were compared between the groups using nonparametric Mann-Whitney test. The horizontal bars represent the median values. P values were determined, and those less than .05 were considered significant. (B) Positive correlation between frequencies and absolute numbers of CD3 ϩ V␦2neg ␥␦ T cells and CD8 ϩ CD28 Ϫ CD57 ϩ ␣␤ T cells was detected in the CMV ϩ group. majority of donors, and no significant difference was detected between the groups.
Expanded V␦2negative ␥␦ T cells lyse CMV-infected cells in vitro
Polyclonal V␦2neg ␥␦ T-cell lines were generated from CMVseropositive healthy donors (n ϭ 8) and from a CMV ϩ patient who received a graft from a CMV ϩ donor at 2 separate early time points after transplantation. Monolayers of MRC5 fibroblasts infected with TB40E or VHLE clinical CMV strains were cocultured with V␦2neg cell lines for 4 hours at indicated E:T ratios. V␦2neg ␥␦ T cells showed specific cytotoxicity by lysis of CMV-infected but not uninfected fibroblasts. Irrespective of the CMV serostatus of the allogeneic feeder cell donors, V␦2neg cell lines were consistently able to lyse CMV-infected targets ( Figure 7A ). In contrast, V␦2pos ␥␦ T cells were unable to lyse CMV-infected fibroblasts (data not shown). The specific reactivity of V␦2neg cells against CMV was supported by the lack of specific lysis of HSV-infected fibroblasts (data not shown).
Because ␥␦ T cells represent part of the innate immune response, we investigated whether CMV-reactive V␦2neg ␥␦ T cells could be generated from CMV-seronegative healthy donors. Polyclonal V␦2neg ␥␦ T-cell lines were successfully raised from multiple CMV-seronegative donors (n ϭ 9) and cocultured with CMV-infected or uninfected MRC5 fibroblasts and showed cytotoxicity ( Figure 7A) .
To assess the involvement of the TCR and CD3 in the cell lysis, V␦2neg ␥␦ T-cell lines were cocultured with CMVinfected fibroblasts in the absence or presence of blocking anti-TCR-␥␦ and anti-CD3 antibodies. Interestingly, we were unable to block the specific lysis of CMV-infected targets ( Figure 7B ). These results suggest that other antigens and cell interactions are involved in the target killing. However, blocking of CD3, TCR-␥␦, and NKG2D separately or in combination inhibited the release of INF␥ by T cells confirming that activation of V␦2neg ␥␦ T cell is mediated through the TCR/CD3 ( Figure 7C ).
Discussion
It has been known that human ␥␦ T cells display potent antiviral reactivity against several different viruses. 36 Elevated numbers of ␥␦ T cells have been previously reported in patients with HIV, [37] [38] [39] [40] EBV, 41, 42 and CMV infections. [27] [28] [29] [30] This study demonstrates the impact of the patient-donor CMV status on the immune reconstitution of the ␥␦ T-cell subsets in patients after SCT. Our results are the first to demonstrate that the expansion of V␦2neg ␥␦ T cells is the result of ongoing an active anti-CMV response in patients after allogeneic transplantations.
In line with the recent report by Pitard et al, 30 we confirmed the finding of significantly increased numbers of V␦2neg ␥␦ T cells 43 in CMV ϩ healthy volunteers compared with CMV Ϫ donors, suggesting an involvement of V␦2neg ␥␦ T cells in anti-CMV responses in healthy immunocompetent persons. The expansions of V␦2neg ␥␦ T cells were shown to be independent of those of CMV-specific ␣␤ T cells in CMV ϩ healthy donors. Patients with episodes of CMV reactivation presented large and long-lasting expansions of V␦2neg ␥␦ T cells, suggesting a protective role in CMV infection. No correlation between V␦2neg ␥␦ T cells and the CMV-specific ␣␤ T cells has been found in patients with CMV reactivation, suggesting similar functional properties of both cell populations against CMV.
Previous studies have reported expansion of ␥␦ T cells during viral infections after allogeneic SCT. Cela et al 43 documented high frequencies and numbers of total ␥␦ T cells in patients with viral and fungal infections after T-cell depleted bone marrow transplantations, although the relative contribution of V␦2neg ␥␦ T cells was not reported. Another study described by Hirokawa et al 44 reported the expansion of V␦1 but not V␦2 ␥␦ T cells during the first 2 months after transplantation. In the patient cohort, all but one patient was CMV ϩ so the effect of CMV reactivation could not be assessed. In the follow-up paper, 61% of allogeneic SCT patients showed skewed V␦1 TCR Figure 6 . CDR3 spectratyping analysis of the TCR-␦ chains in healthy adult donors and in patients after transplantation. Profiles of the CDR3 distribution of the V␦1 (A), V␦2 (B), and V␦3 (C) subsets were generated from sorted CD4 Ϫ CD8 Ϫ cells from CMV ϩ (n ϭ 13) and CMV Ϫ (n ϭ 12) healthy donors. Longitudinal study of the ␥␦ T-cell repertoire of the V␦1, V␦2, and V␦3 subsets was carried out in patients during the first 12 months after SCT. (D) TCR V␥8 chains profiles were generated from CMV ϩ (n ϭ 19) and CMV Ϫ (n ϭ 16) healthy donors. Results are presented as mean Ϯ SD. N indicates healthy adult; Pt, patients; and 3/12, 6/12, and 12/12 indicate the 3-, 6-, and 12-month time points after transplantation, respectively. Samples were analyzed using nonparametric Mann-Whitney test, and P values were determined. P values less than .05 were considered significant.
repertoire, but there was no association between V␦1 TCR clonality and serologic status of CMV or EBV. 45 Substantial expansions of V␦2neg ␥␦ T cells accounting for up to 30% of peripheral T cells have been reported in CMV ϩ recipients of renal allografts 27 and have been associated with resolution of CMV infection. 29 This report is the first to confirm this finding in the allogeneic SCT setting.
To analyze the impact of the CMV seropositivity on the repertoire of the ␥␦ T cells, we used TCR-␦ chain CDR3 spectratyping for the TCR-␦ chains V␦1, V␦2, and V␦3 subsets in patients after transplantation and in healthy donors. The majority of healthy CMV ϩ donors presented oligoclonal distribution of the V␦1 profiles in addition to 2 monoclonal expansions. V␦2pos cells displayed predominantly polyclonal TCR repertoire in both CMV ϩ and CMV Ϫ persons. Similar data have been documented recently. 30 Highly restricted distributions of the V␦3 profiles were observed in healthy adults and patients regardless of their CMV serostatus. Marked expansion of V␦3 cells with a highly restricted TCR repertoire has been documented in CMV ϩ renal allograft recipients. 27 Our results indicate that expanded V␦2neg ␥␦ T cells in CMV infection carry some degree of skewed ␥␦ TCR rearrangements in healthy donors, and similar patterns of generally restricted oligoclonal distribution of the V␦2neg ␥␦ T cells were observed in CMV ϩ/ϩ patients persisting during the first 12 months after transplantation. The fact that no significant differences in TCR repertoire diversity of expanded V␦2neg ␥␦ T cells were detected between patients with or without CMV reactivation suggests that the anti-CMV response of ␥␦ T cells does not select unique monoclonal TCRs. This lack of clonal selection of the ␥␦ TCR is similar to earlier reports showing CDR3 independent V␦1 selection in HIV patients 40, 46 and in hepatitis C virus-infected patients. 47 Of note, large expansions of V␦2neg ␥␦ T cells were detected also in 2 CMV Ϫ/Ϫ patients with recurrent infections. Dramatic expansion of V␦1 ␥␦ T cells in CMV Ϫ patient with a syndrome of recurrent fever and infection of unknown etiology has been reported. 48 A recent report by Vermijlen et al described an expansion of V␥8V␦1 cells in CMV-infected newborns. 33 We have analyzed a cohort of 35 healthy adults and found no significant difference between CMV ϩ and CMV Ϫ donors.
To address the question whether expanded V␦2neg ␥␦ T cells were CMV-reactive, polyclonal V␦2neg ␥␦ T-cell lines were raised from CMV-seropositive and also CMV-seronegative healthy donors, and both showed cytotoxicity toward CMV-infected MRC5 fibroblasts. In addition, V␦2neg ␥␦ T-cell lines raised from a CMV-seropositive patient at 2 different time points early after transplantation were also able to kill CMV-infected fibroblasts at the similar level to lines generated from healthy donors. These results represent the first evidence for CMV-reactive ␥␦ T cells in recipient with CMV reactivation early postallogeneic transplantation.
In conclusion, this is the first report examining the role of ␥␦ T cells in immune responses to CMV reactivation in patients after allogeneic SCT. The results in this study demonstrate the antiviral capacity of V␦2neg ␥␦ T cells directed toward CMVinfected cells, which could be potentially explored as a novel immunotherapy in allogeneic transplantation recipients. Reactivation of CMV infection, which usually occurs in more than 70% in immunocompromised CMV-seropositive patients, is being treated by adoptive cellular therapy developed and extended in our center consisting of infusion of CMV-specific ␣␤ T lymphocytes after transplantation. 49, 50 Parallel to the cellular therapy, CMV-reactive V␦2neg ␥␦ T cells could be generated from CMV-seropositive donors and used adoptively in patients with CMV reactivation without a risk of graft-versushost disease, in addition providing the beneficial GvL effect to patients' immune reconstitution postallogeneic SCT. CMVreactive V␦2neg ␥␦ T cells could be also generated from CMV-seronegative donors for CMV-seropositive recipients who are lacking protective CMV immunity and are at greater risk of CMV reactivation. The novel observation of significant expansions of V␦2neg ␥␦ T cells in CMV-seropositive patients undergoing CMV reactivation after allogeneic SCT will require further investigations to fully determine the role of ␥␦ T cells in immune responses to CMV infection. Additional studies are currently under way in our laboratory. (A) Monolayers of uninfected MRC5 fibroblasts or infected with TB40E or VHLE clinical CMV strains were cocultured at indicated E:T ratios for 4 hours at 37°C with V␦2neg ␥␦ T polyclonal cell lines raised from CMV-seropositive healthy donors (n ϭ 8, ), from a CMV-seropositive transplantation recipient (f) at 2 early time points after transplantation and CMV-seronegative healthy donors (n ϭ 9, ). Lysis of uninfected cells as control is shown (Ⅺ). Results are the mean of specific lysis of culture duplicates. CV was always less than 15%. (B) V␦2neg ␥␦ T-cell lines were cocultured with CMV-infected fibroblasts in the absence or presence of blocking anti-TCR-␥␦ and anti-CD3 antibodies. Uninfected cell lysis (white bar), control as lysis with no blocking (gray bar), TCR blocking (dark gray bar), and CD3 blocking (black bar). (C) IFN-␥ secretion detected in the culture supernatants after 6-hour stimulation coculture of V␦2neg ␥␦ T-cell line with CMV-infected fibroblasts at 10:1 E:T in the absence ( ) or presence of anti-CD3 (Ⅺ), anti-NKG2D, anti-TCR-␥␦ blocking ( ), and TCR/CD3/NKG2D (f).
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